-The Conference Forum is pleased to announce the launch of the 3rd annual Clinical Trial Collaborations conference in Boston on April 9-11, 2018. Industry veteran, Dr Jeremy Chadwick, Group VP, Clinical Development Operations, Shire Pharmaceuticals, and conference chair, Dr Murray Abramson address in a fireside chat what it takes to develop strateg
Factory Mutual Insurance Co. increased its stake in Alexion Pharmaceuticals, Inc. by 104.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. Factory Mutual Insurance Co. owned approximately 0.16% of Alexion Pharmaceuticals worth $42,873,000 as of its most recent filing with the..
Orphazyme A/S, a Danish biotech company listed on Nasdaq Copenhagen, with a late-stage, orphan-drug pipeline, today announced that arimoclomol has been granted rare pediatric disease designation by the US Food and Drug Administration for the treatment of Niemann-Pick disease Type C. Arimoclomol has now been granted orphan drug, fast track, and rare
By a News Reporter-Staff News Editor at Marketing Weekly News Arvinas LLC, a private biotechnology company focused on creating a new class of drugs based on protein degradation, announced a research collaboration and license agreement with Pfizer Inc. for the discovery and development of drug candidates using Arvinas' proprietary PROTAC Platform,
This clinical trial that received the approval of the FDA is Averas latest collaboration as part its membership in the Worldwide Innovative Networking Consortium. This latest step in our collaboration with WIN represents one clinical trial but is part of our larger goal to revolutionize cancer care through personalized medicine, said Benjamin Solom
Biohaven Pharmaceutical Holding Company Ltd. and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., announced that the US Food and Drug Administration has notified the company that it may proceed with its clinical investigation of BHV-5000. BHV-5000 is a low trapping, potent N-methyl-D-aspartate receptor antagonist licensed to Biohaven fr
Cadila Healthcare reported that its Dabhasa plant has cleared a USFDA audit with zero observations. Cadila Healthcare is currently trading at Rs447.15, up by Rs11.05 or 2.53% from its previous closing of Rs436.1 on the BSE. Cadila Healthcare is a fully-integrated, pharmaceutical company with strong presence in the formulations and CRAMS businesses.
Freeline Therapeutics, is a a global biopharmaceutical company focused on the development of adeno-associated virus based gene therapies. Establishing this capability at the Catapult Manufacturing Centre enables us to meet this aim and to drive our growing pipeline forward. said Jan Thirkettle, Chief Development Officer, Freeline Therapeutics.
Albany, NY 01/19/2018 Lately, the global pediatric vaccination market has been exhibiting a robust growth. Various upcoming child healthcare programs by UNICEF and the WHO are likely to boost this market in the near future. North America, Europe, Asia Pacific, and the Rest of the World are the key regional markets for pediatric vaccines in th
BOULDER, Colo. and CASTRES, France, Jan. 20, 2018/ PRNewswire/ Array BioPharma Inc. and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients
The Department of Justice announced today that a federal court in New Jersey imposed a $5 million civil penalty and entered a consent decree of permanent injunction against Dr. Reddys Laboratories Inc. Dr. Reddys is the North American subsidiary of Dr. Reddys Laboratories Limited, a pharmaceutical company headquartered in India. The case involves..
The share price of Dong-A ST, a pharmaceutical company, has been surging after the company announced its deal to transfer technology of DA-9801, a diabetic neuropathy treatment, to NeuroBo Pharmaceuticals, Thursday. Under the agreement, Dong-A ST will receive $2 million and a 5 percent stake in NeuroBo, with milestones of up to $178 million, follow
Albany, NY 01/19/2018 Dry powder inhalers are used to deliver drugs in dry powdered form to the lungs of patients suffering from respiratory disorders. Pulmonary drug delivery has been gaining attention and acceptance in the past few years in the treatment of respiratory disorders due to advantages such as faster drug absorption, high bioavai
Doug Ducey wants lawmakers to enact a grab-bag of laws and authorize new regulations- many on doctors- in a bid to curb opioid abuse and overdoses. Legislation being crafted for a special legislative session this coming week includes:. Christina Corieri, the governor's health adviser, said the package was crafted with input from various interests,
New York, NY 01/19/2018 Ebola viral infection was first observed in The Democratic Republic of Congo in 1976. Ebola is a viral disease which frequently causes lethal haemorrhagic fever in humans. Top drug companies such as Hemispherx Biopharma, Biochryst Pharmaceuticals, Nano Vircides, Serepata Therapeutics, NewLink Genetics and Mapp Biopharm
Amgen and Allergan plc have that the European Commission has granted marketing authorisation for MVASI. The European Commissions approval of MVASI marks a significant milestone for both Amgen and the oncology community, providing a biosimilar for a medicine which is used across multiple types of cancer, said Sean E Harper, MD, executive vice presid
Exelixis, Inc. today announced the presentation of updated results from the Genentech- sponsored phase 1 b clinical trial of cobimetinib, an Exelixis- discovered MEK inhibitor, in combination with atezolizumab, an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, in patients with metastatic colorectal cancer.
By a News Reporter-Staff News Editor at Marketing Weekly News Foresee Pharmaceuticals Co., Ltd., a Taiwan and US-based biopharmaceutical company and Megapharm Ltd., a leading Israel- based biopharmaceutical company, announced that they have entered into an exclusive license and distribution agreement for the commercialisation in Israel and the...
Genus Lifesciences, Allentown, Pennsylvania, has been assigned a patent developed by two co-inventors for "pharmaceutical compositions and methods of using the same." The co-inventors are Jeffrey M. Moshal, Allentown, Pennsylvania, and Michael Libman, Allentown, Pennsylvania. Written by Diptimayee Mishra; edited by Sudarshan Harpal.
The Japanese government is planning new measures to help Japanese companies construct pharmaceutical factories in Asian countries, where labour costs are lower than in Japan, to encourage the production of more generic drugs. The Headquarters for Healthcare and Medical Strategy Promotion chaired by Prime Minister Shinzo Abe is proceeding with the s
Lundbeck Korea said it would conduct a phase-3 clinical trial on antidepressant Brintellix for pediatric patients with a major depressive disorder in Korea. The Ministry of Food and Drug Safety recently approved the trial plan, which will assess the efficacy of Brintellix 10 mg, 15 mg, and 20 mg on 12 patients aged between 12 and 17.. Jointly devel
-MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the expansion of its executive committee with the appointment of Cynthia Ladd as General Counsel. Cynthia brings substantial experience as a biotech executive and expertise in.
In a new paper, researchers from the University of Glasgow present for the first time a new approach to the manufacture of pharmaceuticals that can be made using a digital code. In the paper, the team of researchers from the University`s School of Chemistry demonstrate the potential of the system by producing the pharmaceutical Baclofen, a muscle r
Many of the major not-for-profit hospital groups have tried their hand an manufacturing and making generics to combat the shortages of medicines as well as the high costs of branded medications. This move bypasses the monopoly held by the pharmaceutical companies. Hospital groups that are joining hands in this venture include Intermountain Health,.
The deal with Novartis` subsidiary Sandoz comes after Biocon resolved problems at its manufacturing facility that forced it to withdraw EU filings for biosimilar versions of Roche`s breast cancer drug Herceptin and Amgen`s long-acting white cell booster Neulasta last August at the request of the EMA. The companies will share responsibility for...